{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:23:16Z","timestamp":1784251396960,"version":"3.55.0"},"reference-count":65,"publisher":"Royal College of General Practitioners","issue":"736","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Gen Pract"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Adverse drug reaction (ADR) related to angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may negatively affect patients\u2019 treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the impact of ACEIs\/ARBs-related ADR consultation on cardiovascular disease (CVD) events and all-cause mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and setting<\/jats:title><jats:p>Propensity score-matched cohort study of ACEIs\/ARBs between 2004 and 2019 using UK IQVIA medical research data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>ADR consultations were identified using standardised designated codes. Propensity scores were calculated based on comorbidities, concomitant medications, frailty, and polypharmacy. Cox\u2019s proportional hazard regression model was used to compare the outcomes between patients in ADR and non-ADR groups. In the secondary analysis, treatment- pattern changes following the ADR were examined and the subsequent outcomes were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 1 471 906 eligible users of ACEIs\/ARBs, 13 652 (0.93%) patients had ACEIs\/ARBs- related ADR consultation in primary care. Patients with ACEIs\/ARBs-related ADR consultation had an increased risk of subsequent CVD events and all- cause mortality in both primary prevention (CVD events: adjusted hazard ratio [aHR] 1.22, 95% confidence interval [CI] = 1.05 to 1.43; all-cause mortality: aHR 1.14, 95% CI = 1.01 to 1.27) and secondary prevention cohorts (CVD events: aHR 1.13, 95% CI = 1.05 to 1.21; all-cause mortality: aHR 1.15, 95% CI = 1.09 to 1.21). Half (50.19%) of patients with ADR continued to use ACEIs\/ARBs, and these patients had a reduced risk of mortality (aHR 0.88, 95% CI = 0.82 to 0.95) compared with those who discontinued using ACEIs\/ARBs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides information on the burden of ADR on patients and the health system. The findings call for additional monitoring and treatment strategies for patients affected by ADR to mitigate the risks of adverse clinical outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3399\/bjgp.2023.0153","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T16:26:32Z","timestamp":1688487992000},"page":"e832-e842","source":"Crossref","is-referenced-by-count":12,"title":["Impact of ACEIs and ARBs-related adverse drug reaction on patients\u2019 clinical outcomes: a cohort study in UK primary care"],"prefix":"10.3399","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0066-9746","authenticated-orcid":false,"given":"Widya N","family":"Insani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-2272","authenticated-orcid":false,"given":"Cate","family":"Whittlesea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-6262","authenticated-orcid":false,"given":"Chengsheng","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-1942","authenticated-orcid":false,"given":"Kenneth KC","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2058-4096","authenticated-orcid":false,"given":"Matthew","family":"Adesuyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-1605","authenticated-orcid":false,"given":"Sarah","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-7267","authenticated-orcid":false,"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"2023102617252835000_73.736.e832.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.13766"},{"issue":"6","key":"2023102617252835000_73.736.e832.2","first-page":"232","article-title":"Overall prescription medication use among adults: findings from the Survey of the Health of Wisconsin","volume":"113","author":"Che","year":"2014","journal-title":"WMJ"},{"issue":"6","key":"2023102617252835000_73.736.e832.3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/pds.3947","article-title":"Increasing use of prescription drugs in the United Kingdom","volume":"25","author":"Zhang","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023102617252835000_73.736.e832.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5310"},{"key":"2023102617252835000_73.736.e832.5","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001063"},{"key":"2023102617252835000_73.736.e832.6","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"2023102617252835000_73.736.e832.7","unstructured":"National Institute for Health and Care Excellence (2021) Chronic kidney disease: assessment and management NG203 (NICE, London) https:\/\/www.nice.org.uk\/guidance\/ng203 (accessed 24 Aug 2023)."},{"key":"2023102617252835000_73.736.e832.8","unstructured":"National Institute for Health and Care Excellence (2022) Hypertension in adults: diagnosis and management NG136 (NICE, London) https:\/\/www.nice.org.uk\/guidance\/ng136 (accessed 24 Aug 2023)."},{"key":"2023102617252835000_73.736.e832.9","unstructured":"National Institute for Health and Care Excellence (2018) Chronic heart failure in adults: diagnosis and management NG106 (NICE, London) https:\/\/www.nice.org.uk\/guidance\/ng106 (accessed 24 Aug 2023)."},{"issue":"5","key":"2023102617252835000_73.736.e832.10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1 Suppl","key":"2023102617252835000_73.736.e832.11","doi-asserted-by":"crossref","first-page":"10A","DOI":"10.1016\/j.amjcard.2009.10.006","article-title":"Progression of cardiovascular damage: the role of renin-angiotensin system blockade","volume":"105","author":"Probstfield","year":"2010","journal-title":"Am J Cardiol"},{"key":"2023102617252835000_73.736.e832.12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001841.pub3"},{"key":"2023102617252835000_73.736.e832.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.07.108."},{"issue":"5","key":"2023102617252835000_73.736.e832.14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ndt\/gfz263","article-title":"Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population","volume":"36","author":"Wetmore","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2023102617252835000_73.736.e832.15","doi-asserted-by":"crossref","unstructured":"Tsang C Bottle A Majeed A Aylin P (2013) Adverse events recorded in English primary care: observational study using the General Practice Research Database. Br J Gen Pract, DOI: https:\/\/doi.org\/10.3399\/bjgp13X670660 .","DOI":"10.3399\/bjgp13X670660"},{"key":"2023102617252835000_73.736.e832.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02398.x"},{"key":"2023102617252835000_73.736.e832.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1283-9"},{"issue":"6","key":"2023102617252835000_73.736.e832.18","doi-asserted-by":"crossref","first-page":"e110522204611","DOI":"10.2174\/1573403X18666220511152330","article-title":"An overview of clinically imperative and pharmacodynamically significant drug interactions of renin-angiotensin-aldosterone system (RAAS) blockers","volume":"18","author":"Maideen","year":"2022","journal-title":"Curr Cardiol Rev"},{"key":"2023102617252835000_73.736.e832.19","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.18.1930"},{"key":"2023102617252835000_73.736.e832.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.12.036"},{"key":"2023102617252835000_73.736.e832.21","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.116"},{"key":"2023102617252835000_73.736.e832.22","unstructured":"National Institute for Health and Care Excellence (2023) Hypertension: angiotensin-converting enzyme inhibitors (NICE, London) https:\/\/cks.nice.org.uk\/topics\/hypertension\/prescribing-information\/angiotensin-converting-enzyme-inhibitors (accessed 24 Aug 2023)."},{"key":"2023102617252835000_73.736.e832.23","unstructured":"National Institute for Health and Care Excellence (2023) Hypertension: angiotensin-II receptor blockers (NICE, London) https:\/\/cks.nice.org.uk\/topics\/hypertension\/prescribing-information\/angiotensin-ii-receptor-blockers (accessed 24 Aug 2023)."},{"key":"2023102617252835000_73.736.e832.24","doi-asserted-by":"publisher","DOI":"10.14236\/jhi.v19i4.820"},{"issue":"S1","key":"2023102617252835000_73.736.e832.25","first-page":"37","article-title":"Adverse drug reactions in UK primary care consultations: a retrospective cohort study to evaluate impact on appointments and treatment discontinuation","volume":"28","author":"Chapman","year":"2020","journal-title":"Int J Pharm Pract"},{"issue":"11","key":"2023102617252835000_73.736.e832.26","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1111\/bcp.15438","article-title":"Statin-related adverse drug reactions in UK primary care consultations: a retrospective cohort study to evaluate the risk of cardiovascular events and all-cause mortality","volume":"88","author":"Insani","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2023102617252835000_73.736.e832.27","first-page":"117","article-title":"Recording of adverse events in English general practice: analysis of data from electronic patient records","volume":"18","author":"Tsang","year":"2010","journal-title":"Inform Prim Care"},{"key":"2023102617252835000_73.736.e832.28","doi-asserted-by":"crossref","unstructured":"Blais JE Akyea RK Coetzee A (2021) Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol. BJGP Open, DOI: https:\/\/doi.org\/10.3399\/bjgpopen20X101127 .","DOI":"10.3399\/bjgpopen20X101127"},{"issue":"7","key":"2023102617252835000_73.736.e832.29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/jcm5070062","article-title":"Heart failure: diagnosis, management and utilization","volume":"5","author":"Inamdar","year":"2016","journal-title":"J Clin Med"},{"key":"2023102617252835000_73.736.e832.30","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13205"},{"key":"2023102617252835000_73.736.e832.31","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.200810488"},{"key":"2023102617252835000_73.736.e832.32","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afw039"},{"issue":"3","key":"2023102617252835000_73.736.e832.33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000368191","article-title":"Temporal trends in polypharmacy and hyperpolypharmacy in older New Zealanders over a 9-year period: 2005\u20132013","volume":"61","author":"Nishtala","year":"2015","journal-title":"Gerontology"},{"key":"2023102617252835000_73.736.e832.34","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"2023102617252835000_73.736.e832.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.1363"},{"issue":"1","key":"2023102617252835000_73.736.e832.36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/em-2012-0006","article-title":"Comparison of approaches to weight truncation for marginal structural Cox models","volume":"2","author":"Xiao","year":"2013","journal-title":"Epidemiologic Methods"},{"key":"2023102617252835000_73.736.e832.37","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7501"},{"key":"2023102617252835000_73.736.e832.38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252161"},{"issue":"4","key":"2023102617252835000_73.736.e832.39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/ehjcvp\/pvy017","article-title":"Early occurrence of drug intolerance as risk factor during follow-up in patients with acute coronary syndrome or coronary revascularization","volume":"4","author":"Albani","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023102617252835000_73.736.e832.40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j791"},{"key":"2023102617252835000_73.736.e832.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.07.010"},{"issue":"11 Suppl","key":"2023102617252835000_73.736.e832.42","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"issue":"2","key":"2023102617252835000_73.736.e832.43","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2023102617252835000_73.736.e832.44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ahj.2021.09.014","article-title":"Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes","volume":"243","author":"Xu","year":"2022","journal-title":"Am Heart J"},{"issue":"1","key":"2023102617252835000_73.736.e832.45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12882-019-1611-8","article-title":"Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level \u22655.5 mmol\/L: pooled analysis from two phase 3 trials","volume":"20","author":"Amin","year":"2019","journal-title":"BMC Nephrol"},{"key":"2023102617252835000_73.736.e832.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411487"},{"key":"2023102617252835000_73.736.e832.47","unstructured":"National Institute for Health and Care Excellence (2022) Sodium zirconium cyclosilicate for treating hyperkalaemia TA559 (NICE, London) https:\/\/www.nice.org.uk\/guidance\/ta599\/chapter\/1-Recommendations (accessed 24 Aug 2023)."},{"key":"2023102617252835000_73.736.e832.48","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261835"},{"key":"2023102617252835000_73.736.e832.49","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(00)90037-1"},{"key":"2023102617252835000_73.736.e832.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032292"},{"key":"2023102617252835000_73.736.e832.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(99)00165-X"},{"key":"2023102617252835000_73.736.e832.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61242-8"},{"issue":"8","key":"2023102617252835000_73.736.e832.53","first-page":"CD009096","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"2014","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2023102617252835000_73.736.e832.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801317"},{"key":"2023102617252835000_73.736.e832.55","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht151"},{"key":"2023102617252835000_73.736.e832.56","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000065"},{"key":"2023102617252835000_73.736.e832.57","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"2023102617252835000_73.736.e832.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806182"},{"issue":"9","key":"2023102617252835000_73.736.e832.59","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/bcp.13312","article-title":"Impact of adverse drug events and treatment satisfaction on patient adherence with antihypertensive medication \u2014 a study in ambulatory patients","volume":"83","author":"Berhe","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2023102617252835000_73.736.e832.60","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012818"},{"key":"2023102617252835000_73.736.e832.61","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-009-1228-x"},{"key":"2023102617252835000_73.736.e832.62","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpv185"},{"key":"2023102617252835000_73.736.e832.63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313220"},{"key":"2023102617252835000_73.736.e832.64","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002606"},{"issue":"5","key":"2023102617252835000_73.736.e832.65","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s11255-020-02452-8","article-title":"Factors affecting medication adherence among pre-dialysis chronic kidney disease patients: a systematic review and meta-analysis of literature","volume":"52","author":"Seng","year":"2020","journal-title":"Int Urol Nephrol"}],"container-title":["British Journal of General Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGP.2023.0153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:27:43Z","timestamp":1698366463000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgp.org\/lookup\/doi\/10.3399\/BJGP.2023.0153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":65,"journal-issue":{"issue":"736","published-online":{"date-parts":[[2023,10,26]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.3399\/BJGP.2023.0153"],"URL":"https:\/\/doi.org\/10.3399\/bjgp.2023.0153","relation":{},"ISSN":["0960-1643","1478-5242"],"issn-type":[{"value":"0960-1643","type":"print"},{"value":"1478-5242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]}}}